Literature DB >> 31102937

Qing Chang Hua Shi granule ameliorate inflammation in experimental rats and cell model of ulcerative colitis through MEK/ERK signaling pathway.

Lei Zhu1, Lu-Ming Dai1, Hong Shen2, Pei-Qing Gu1, Kai Zheng1, Ya-Jun Liu1, Lu Zhang1, Jia-Fei Cheng1.   

Abstract

Ulcerative colitis (UC), a bowel disease with significant morbidity, is associated with inflammation. In this study, the effect of Qingchang Huashi granule (QCHS) on UC and its underlying mechanisms were explored using both animal and cell culture experiments. A rat UC model was induced with trinitro-benzene-sulfonic acid (TNBS), concentrations of the cytokines IL-1α, IL-6, IL-8, IL-1β, and TNF-α were significantly up-regulated and the concentrations of IL-4, IL-10, and IL-13 were significantly down-regulated compared with the control group (P < 0.05). In contrast, the QCHS and salicylazosulfapyridine (SASP) groups reversed these modulations (P < 0.05). A UC cell model in HT-29 cells was generated using TNF-α combined with lipopolysaccharide treatment. Cells treated with QCHS were used to investigate the possible mechanisms. The expression of apoptosis-related proteins, including Bax/Bcl-2, caspase-3, caspase-9, Fas/Fas-L, and Rafl in the QCHS and SASP groups, were significantly lower than that in the control group in both animal and cell experiments (P < 0.05). In addition, the in vitro results indicate changes in these indicators mediate the MEK/ERK signaling pathways via SGK1. Our results suggested that QCHS could be beneficial in preventing UC progression as an alternative drug for UC treatment.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Apoptosis; Inflammation; Mechanism; Qing Chang Hua Shi granule; Ulcerative colitis

Mesh:

Substances:

Year:  2019        PMID: 31102937     DOI: 10.1016/j.biopha.2019.108967

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

Review 1.  Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines.

Authors:  Peng-De Lu; Yong-Hua Zhao
Journal:  Chin Med       Date:  2020-02-10       Impact factor: 5.455

2.  Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial.

Authors:  Zhaofeng Shen; Kai Zheng; Jiandong Zou; Peiqing Gu; Jing Xing; Lu Zhang; Lei Zhu; Hong Shen
Journal:  Trials       Date:  2021-01-13       Impact factor: 2.279

Review 3.  Natural Products Modulate Cell Apoptosis: A Promising Way for the Treatment of Ulcerative Colitis.

Authors:  Chenhao Liu; Yiwei Zeng; Yulong Wen; Xinggui Huang; Yi Liu
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

4.  Modulating gut dysbiosis and mitochondrial dysfunction in oxazolone-induced ulcerative colitis: the restorative effects of β-glucan and/or celastrol.

Authors:  Omnia Safwat El-Deeb; Rasha Osama El-Esawy; Hanan Alsaeid Al-Shenawy; Heba Bassiony Ghanem
Journal:  Redox Rep       Date:  2022-12       Impact factor: 4.412

5.  Knockdown of TRPM7 attenuates apoptosis and inflammation in neonatal necrotizing enterocolitis model cell IEC-6 via modulating TLR4/NF-κB and MEK/ERK pathways.

Authors:  Lu An; Juan Li; Bing Liu; Junpeng Hui; Qiang Zhang; Xin Zhang; Qi Wang
Journal:  Iran J Basic Med Sci       Date:  2022-08       Impact factor: 2.532

6.  Yes-activated protein promotes primary resistance of BRAF V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors.

Authors:  Meng Su; Lei Zhan; Yong Zhang; Jingdong Zhang
Journal:  J Gastrointest Oncol       Date:  2021-06

7.  Qingchang Huashi granule ameliorates experimental colitis via restoring the dendritic cell-mediated Th17/Treg balance.

Authors:  Jia Jia; Kai Zheng; Hong Shen; Jiangyi Yu; Ping Zhu; Shihai Yan; Yi Xu; Lei Zhu; Yuelin Lu; Peiqing Gu; Wan Feng
Journal:  BMC Complement Med Ther       Date:  2020-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.